{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T21:29:03Z","timestamp":1777411743917,"version":"3.51.4"},"reference-count":12,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2006,8,25]],"date-time":"2006-08-25T00:00:00Z","timestamp":1156464000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["obgyn.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJOG"],"published-print":{"date-parts":[[2006,9]]},"abstract":"<jats:p>Conventional therapies for human papillomavirus infection aim to remove clinically apparent lesions, while latent infection may remain, representing a threat for transmission and carcinogenesis. The use of a systemic agent may more effectively control the virus. We conducted a randomised placebo\u2010controlled study to investigate the efficacy and safety of oral inociplex in the treatment of cervical condylomata acuminata (CA) that had been resistant to conventional therapies. Thirty\u2010eight white European women, aged 20\u201343 years, with genital warts of the cervix, refractory to at least one conventional therapy, were randomly assigned to receive either inosiplex, 50 mg\/kg daily peros for 12 weeks (group 1), or placebo (group 2). Of the 17 evaluable group 1 women, 4 responded to the treatment completely, 7 responded partially and 6 did not respond. Of the 19 group 2 women, none responded to the treatment completely, 3 responded partially and 16 did not respond. The therapeutic difference between women receiving active and placebo therapy was statistically significant (\u03c7<jats:sup>2<\/jats:sup>= 6.69, <jats:italic>P<\/jats:italic> &lt; 0.01) and remained significant when an intention\u2010to\u2010treat analysis was performed (\u03c7<jats:sup>2<\/jats:sup>= 7.69, <jats:italic>P<\/jats:italic> &lt; 0.01). None of the complete responders experienced recurrence during the 12\u2010month follow up. Adverse effects were mild and resolved upon completion of therapy. Compared with placebo, inosiplex showed considerable efficacy with insignificant and reversible adverse effects and without recurrences. Inosiplex may represent an efficacious and safe alternative systemic form of therapy for cervical genital warts.<\/jats:p>","DOI":"10.1111\/j.1471-0528.2006.01041.x","type":"journal-article","created":{"date-parts":[[2006,8,25]],"date-time":"2006-08-25T23:32:12Z","timestamp":1156548732000},"page":"1088-1091","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Short communication: Oral inosiplex in the treatment of cervical condylomata acuminata: a randomised placebo\u2010controlled trial"],"prefix":"10.1111","volume":"113","author":[{"given":"S","family":"Georgala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"AC","family":"Katoulis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Befon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Georgala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Rigopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,8,25]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1080\/00313020212469"},{"key":"e_1_2_5_3_2","first-page":"103","article-title":"Combined therapy trial with interferon alpha\u20102a and ablative therapy in the treatment of anogenital warts","volume":"72","author":"Armstrong DKB","year":"1996","journal-title":"Genitourin Med"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198632050-00001"},{"key":"e_1_2_5_5_2","first-page":"352","article-title":"Immunotherapy of genital warts with inosine pranobex (Imunovir): preliminary study","volume":"62","author":"Mohanty KC","year":"1986","journal-title":"Genitourin Med"},{"key":"e_1_2_5_6_2","first-page":"383","article-title":"Immunotherapy of genital warts with inosine pranobex and conventional treatment: double blind placebo controlled study","volume":"64","author":"Davidson\u2010Parker J","year":"1988","journal-title":"Genitourin Med"},{"key":"e_1_2_5_7_2","first-page":"681","article-title":"Treatment of cervical and vulvar condylomata by CO2 laser with an immunostimulant","volume":"79","author":"Sadoul G","year":"1984","journal-title":"Rev Fr Gynecol Obstet"},{"key":"e_1_2_5_8_2","first-page":"497","article-title":"Isoprinosine in the treatment of genital warts","volume":"12","author":"O\u2019Neill BB","year":"1988","journal-title":"Cancer Detect Prev"},{"key":"e_1_2_5_9_2","first-page":"123","article-title":"Inosiplex (isoprinosine): a review of its immunological and clinical effects in disease","volume":"6","author":"Wybran J","year":"1982","journal-title":"Adv Pharmacol Ther"},{"key":"e_1_2_5_10_2","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.4049\/jimmunol.121.3.1184","article-title":"Inosiplex a stimulating agent for normal human T cells and human leukocytes","volume":"121","author":"Wybran J","year":"1978","journal-title":"J Immunol"},{"key":"e_1_2_5_11_2","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1128\/iai.13.2.382-387.1976","article-title":"Isoprinosine augmentation of phytohemagglutinin\u2010induced lymphocyte proliferation","volume":"13","author":"Hadden JW","year":"1976","journal-title":"Infect Immun"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0192-0561(82)90043-1"},{"key":"e_1_2_5_13_2","first-page":"109","article-title":"A recent review on in vitro and in vivo immunological activities of methisoprinol","volume":"10","author":"Morin A","year":"1982","journal-title":"Allergol Immunopathol (Madr)"}],"container-title":["BJOG: An International Journal of Obstetrics &amp; Gynaecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1471-0528.2006.01041.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1471-0528.2006.01041.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T20:41:01Z","timestamp":1697056861000},"score":1,"resource":{"primary":{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/10.1111\/j.1471-0528.2006.01041.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8,25]]},"references-count":12,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["10.1111\/j.1471-0528.2006.01041.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1471-0528.2006.01041.x","archive":["Portico"],"relation":{},"ISSN":["1470-0328","1471-0528"],"issn-type":[{"value":"1470-0328","type":"print"},{"value":"1471-0528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,8,25]]},"assertion":[{"value":"2006-08-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}